203 related articles for article (PubMed ID: 8962203)
1. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
[No Abstract] [Full Text] [Related]
2. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
[No Abstract] [Full Text] [Related]
3. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
4. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
[No Abstract] [Full Text] [Related]
5. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
Langrehr JM; Lohmann R; Raakow R; Jonas S; Klupp J; Bechstein WO; Neuhaus R; Neuhaus P
Transplant Proc; 2001 May; 33(3):2290-1. PubMed ID: 11377531
[No Abstract] [Full Text] [Related]
6. Soluble e-selectin, ICAM-1, and VCAM-1 levels in renal allograft recipients.
Lebranchu Y; Kapahi P; al Najjar A; Sharobeem R; Valentin JF; Nivet H; Bagros P; Haskard D
Transplant Proc; 1994 Aug; 26(4):1873-4. PubMed ID: 7520609
[No Abstract] [Full Text] [Related]
7. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
8. Induction therapy: why, when, and which agent?
Krischock L; Marks SD
Pediatr Transplant; 2010 May; 14(3):298-313. PubMed ID: 20345609
[TBL] [Abstract][Full Text] [Related]
9. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
Otto G; Hofmann WJ; Gaweco AS; Seelos R; Herfarth C; Meuer S
Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
[No Abstract] [Full Text] [Related]
10. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis.
Lemmens HP; Langrehr JM; Blumhardt G; Lohmann R; Knoop M; Verschl J; Schattenfroh N; Neuhaus R; Hopf U; Bechstein WO
Transplant Proc; 1994 Dec; 26(6):3622-3. PubMed ID: 7527983
[No Abstract] [Full Text] [Related]
11. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation.
Langrehr JM; Lohmann R; Guckelberger O; Müller AR; Raakow R; Nüssler NC; Klupp J; Pfitzmann R; Jonas S; Settmacher U; Steinmüller T; Neuhaus P
Transplant Proc; 2001; 33(1-2):1433-4. PubMed ID: 11267360
[No Abstract] [Full Text] [Related]
12. Monoclonal antibody to anti-VCAM-1 interferes with murine cardiac allograft rejection.
Pelletier R; Ohye R; Kincade P; Ferguson R; Orosz C
Transplant Proc; 1993 Feb; 25(1 Pt 1):839-41. PubMed ID: 7679845
[No Abstract] [Full Text] [Related]
13. Quadruple-drug therapy with antithymocyte globulin in the early postoperative period after liver transplantation.
Schattenfroh N; Lange D; Bechstein WO; Blumhardt G; Lohmann R; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1968-9. PubMed ID: 8470245
[No Abstract] [Full Text] [Related]
14. Treatment of acute rejection.
Adams DH; Neuberger JM
Semin Liver Dis; 1992 Feb; 12(1):80-8. PubMed ID: 1570553
[No Abstract] [Full Text] [Related]
15. Adhesion molecules during adverse events after human liver transplantation.
Mueller AR; Platz KP; Haller GW; Schumacher G; Rayes N; Schumacher C; Neuhaus P
Transplant Proc; 1997 Nov; 29(7):2822-4. PubMed ID: 9365576
[No Abstract] [Full Text] [Related]
16. Use of antilymphocyte induction therapy in liver transplantation.
Wall WJ
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S64-70. PubMed ID: 10431019
[TBL] [Abstract][Full Text] [Related]
17. Prolongation of hepatic allograft survival with antibodies to ICAM-1 and LFA-1.
Harihara Y; Sakamoto H; Sanjo K; Otsubo O; Watanabe G; Idezuki Y
Transplant Proc; 1994 Aug; 26(4):2258. PubMed ID: 7915063
[No Abstract] [Full Text] [Related]
18. Expression of adhesion molecules in allograft renal dysfunction: a distinct diagnostic pattern in rejection and cyclosporine nephrotoxicity.
Mampaso F; Marcen R; Molina A; Pascual J; Martin A; Bricio T
Transplant Proc; 1994 Oct; 26(5):2859-60. PubMed ID: 7524222
[No Abstract] [Full Text] [Related]
19. Antithymocyte globulin or interleukin 2 receptor antibody for immunosuppressive induction therapy after orthotopic liver transplantation: a follow-up study.
Keck H; Langrehr JM; Knoop M; Lohmann R; Neuhaus P
Transplant Proc; 1993 Aug; 25(4):2701. PubMed ID: 8356721
[No Abstract] [Full Text] [Related]
20. Circulating adhesion molecules and other soluble markers of immune activation in human small bowel and small bowel plus liver transplantation.
Satoh S; Thomson AW; Nakamura K; Warty V; Todo S
Transplant Proc; 1994 Jun; 26(3):1417-8. PubMed ID: 7913263
[No Abstract] [Full Text] [Related]
[Next] [New Search]
